ENSC - Company ID 0001716947
The table below shows Ensysce Biosciences, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.07M | $5.21M | $2.23M | $2.52M | $3.53M | $3.93M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $10.38M | $7.22M | $7.59M | $19.84M | $4.69M | $4.39M |
| SG&A |
Ensysce Biosciences, Inc. reported annual revenue of $5.07M for fiscal year 2025. That is down 2.8% from $5.21M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $3.93M (FY 2020) to $5.07M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.93M |
| $4.72M |
| $5.36M |
| $6.91M |
| $18.71M |
| $1.15M |
| Operating income | -$10.24M | -$6.73M | -$10.72M | -$24.22M | -$19.87M | -$1.61M |
| Income tax | - | - | - | - | - | $244.49K |
| Net income | - | - | - | - | - | $4.31M |
| EPS (diluted) | -$3.98 | -$11.45 | -$70.40 | -$139.42 | -$1.48 | $0.00 |